Vaccine

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian CancerIMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian…

1 week ago
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International ConferenceProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative…

1 week ago
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based VaccinesDyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

2 weeks ago
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business HighlightsInvivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue…

2 weeks ago
Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the ClinicInfinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive DirectorsBringing strengths in strategy, immuno-oncology science execution from bench to…

2 weeks ago
New England Biolabs® Announces 2025 Monarch Nucleic Acid Purification Scholarship Alongside Release of Updated KitsNew England Biolabs® Announces 2025 Monarch Nucleic Acid Purification Scholarship Alongside Release of Updated Kits

New England Biolabs® Announces 2025 Monarch Nucleic Acid Purification Scholarship Alongside Release of Updated Kits

The scholarship will recognize the core tenets of Monarch in awardees' nucleic acid purification research IPSWICH, Mass., March 17, 2025…

2 weeks ago
Micro Bioreactor System Market Booms at 10.7% CAGR – Innovations in Pharma & Biotech Drive Growth | Valuates ReportsMicro Bioreactor System Market Booms at 10.7% CAGR – Innovations in Pharma & Biotech Drive Growth | Valuates Reports

Micro Bioreactor System Market Booms at 10.7% CAGR – Innovations in Pharma & Biotech Drive Growth | Valuates Reports

BANGALORE, India, March 17, 2025 /PRNewswire/ -- Micro Bioreactor System Market is Segmented by Type (48 Parallel, 24 Parallel), by…

2 weeks ago
Curevo Raises $110 Million to Advance Amezosvatein Shingles VaccineCurevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new…

2 weeks ago
Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to SpeakRegistration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

WASHINGTON, March 13, 2025 /PRNewswire/ -- The World Vaccine Congress Washington 2025, the largest and most influential global vaccine event,…

3 weeks ago
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness ProgramsEmergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and…

3 weeks ago